BGM Group (BGM) vs Satellos Bioscience (MSLE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Satellos Bioscience (MSLE) has outperformed BGM Group (BGM) over the past year, gaining 7.4% versus a loss of 96.3%. Over five years, MSLE leads with a -50.8% price change compared with -98.2% for BGM. Satellos Bioscience is the larger company by market cap ($158.9 million vs $143.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BGM | MSLE |
|---|---|---|
| Share price | $10.75 | $7.49 |
| Market cap | $143.56M | $158.91M |
| 1-day change | +10.94% | +1.97% |
| YTD return | -90.29% | +24.91% |
| 1-year return | -96.31% | +7.38% |
| 5-year return | -98.19% | -50.84% |
| EPS (TTM) | $-4.80 | $-2.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $303.00 | $13.40 |
| 52-week low | $6.45 | $5.30 |
| Distance from 52-week high | -96.45% | -44.08% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +244.46% |
| Average volume | 6.11K | 48.44K |
| Shares outstanding | 12.69M | 21.22M |
| Employees | — | 18 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MSLE has outperformed BGM by 103.7 percentage points over the past year.
About BGM Group
BGM stock →BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. The company operates through Diversified Pharmaceutical and Allied Products; AI Solution; and Insurance Business segments.
Health Care · Biotechnology: Pharmaceutical Preparations
About Satellos Bioscience
MSLE stock →Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo.
Health Care · Biotechnology: Pharmaceutical Preparations · 18 employees
BGM vs MSLE FAQ
Which is bigger, BGM Group or Satellos Bioscience?
Satellos Bioscience (MSLE) is larger, with a market capitalization of $158.91M compared with $143.56M for BGM Group (BGM).
Which stock has performed better over the past year, BGM or MSLE?
MSLE returned +7.38% over the past 12 months, compared with -96.31% for BGM (price return, excluding dividends). Past performance does not predict future results.
Are BGM Group and Satellos Bioscience in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.